Claret Asset Management Corp Boosts Holdings in Merck & Co., Inc. $MRK

Claret Asset Management Corp lifted its position in shares of Merck & Co., Inc. (NYSE:MRK) by 117.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 113,461 shares of the company’s stock after purchasing an additional 61,285 shares during the period. Merck & Co., Inc. comprises 1.1% of Claret Asset Management Corp’s portfolio, making the stock its 24th largest position. Claret Asset Management Corp’s holdings in Merck & Co., Inc. were worth $9,523,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Darwin Wealth Management LLC boosted its position in Merck & Co., Inc. by 237.4% in the 3rd quarter. Darwin Wealth Management LLC now owns 307 shares of the company’s stock valued at $26,000 after buying an additional 216 shares during the last quarter. Kilter Group LLC purchased a new stake in shares of Merck & Co., Inc. during the second quarter worth about $27,000. Barnes Dennig Private Wealth Management LLC increased its position in shares of Merck & Co., Inc. by 302.3% during the third quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company’s stock worth $30,000 after acquiring an additional 266 shares during the last quarter. Bare Financial Services Inc lifted its stake in shares of Merck & Co., Inc. by 51.9% in the second quarter. Bare Financial Services Inc now owns 366 shares of the company’s stock worth $29,000 after acquiring an additional 125 shares in the last quarter. Finally, Evolution Wealth Management Inc. acquired a new position in shares of Merck & Co., Inc. in the second quarter worth about $31,000. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Merck & Co., Inc. Stock Performance

Shares of MRK opened at $117.18 on Tuesday. The stock has a market capitalization of $289.72 billion, a PE ratio of 16.10, a price-to-earnings-growth ratio of 2.24 and a beta of 0.27. The business’s fifty day moving average price is $114.42 and its 200 day moving average price is $98.93. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.54 and a quick ratio of 1.30. Merck & Co., Inc. has a 12-month low of $73.31 and a 12-month high of $125.14.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $2.01 by $0.03. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The company had revenue of $16.40 billion for the quarter, compared to analysts’ expectations of $16.19 billion. During the same period in the prior year, the company earned $1.72 earnings per share. The firm’s revenue was up 5.0% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Equities research analysts forecast that Merck & Co., Inc. will post 9.01 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Shareholders of record on Monday, March 16th will be paid a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date is Monday, March 16th. Merck & Co., Inc.’s payout ratio is presently 46.70%.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck exercised an option on Evaxion’s EVX‑B3 infectious disease vaccine program — a sign of active pipeline expansion and BD activity that can add future revenue potential. Evaxion (EVAX) Q4 2025 Earnings Call Transcript
• Positive Sentiment: Merck expanded a multi‑year collaboration with Tempus AI on oncology and drug discovery tools — this reinforces R&D capability and could accelerate discovery programs. Assessing Tempus AI (TEM) Valuation After Expanded Merck Collaboration Announcement
• Positive Sentiment: Market research on Pneumovax 23 highlights expanding adult/geriatric immunization demand and distribution improvements — potential tailwinds for Merck’s vaccine franchise over the medium term. Pneumovax 23 (Merck & Co) Market Research Report 2026
• Neutral Sentiment: Headline market move note — outlets flagged MRK trading above the prior close, reflecting today’s mixed news flow and investor repositioning. Merck (MRK) Rises Higher Than Market: Key Facts
• Neutral Sentiment: Industry/reporting items: analyses and Dow pieces compare Merck with peers and flag sector shifts — useful context but not single‑handedly market moving for MRK. 2 Dow Jones Stocks to Research Further and 1 Facing Headwinds
• Neutral Sentiment: Factbox: drugmakers are increasing U.S. manufacturing and inventory ahead of potential tariffs — could protect supply but may raise near‑term capex and inventory costs. Factbox-Global drugmakers rush to boost US presence as tariff threat looms
• Negative Sentiment: Big headwind: Gardasil sales plunged ~39% in 2025 (weak demand in China) and management does not expect a rebound in 2026 — a meaningful near‑term drag on Merck’s vaccine revenues and top‑line growth. Will Weak Gardasil Sales Continue to Weigh on MRK’s Top Line in 2026?

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on MRK. Wolfe Research upgraded Merck & Co., Inc. from a “peer perform” rating to an “outperform” rating and set a $135.00 price objective for the company in a research note on Thursday, January 8th. TD Cowen increased their target price on Merck & Co., Inc. from $100.00 to $120.00 and gave the company a “hold” rating in a research note on Tuesday, January 20th. Royal Bank Of Canada initiated coverage on shares of Merck & Co., Inc. in a research note on Wednesday, February 25th. They issued an “outperform” rating and a $142.00 price target for the company. BMO Capital Markets upgraded shares of Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $82.00 to $130.00 in a research note on Thursday, December 18th. Finally, Citigroup raised their price objective on shares of Merck & Co., Inc. from $115.00 to $120.00 and gave the stock a “neutral” rating in a report on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $125.88.

Insider Activity at Merck & Co., Inc.

In related news, EVP Richard R. Deluca sold 37,685 shares of the firm’s stock in a transaction that occurred on Friday, February 6th. The stock was sold at an average price of $120.92, for a total value of $4,556,870.20. Following the sale, the executive vice president owned 160,174 shares of the company’s stock, valued at approximately $19,368,240.08. This trade represents a 19.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Caroline Litchfield sold 41,997 shares of the business’s stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $119.61, for a total value of $5,023,261.17. Following the transaction, the chief financial officer owned 90,192 shares of the company’s stock, valued at $10,787,865.12. This represents a 31.77% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 320,176 shares of company stock valued at $38,281,735. 0.09% of the stock is owned by insiders.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.